nach oben

Erschienen in:

27.02.2024 | Original Article

Nomogram for predicting survival of patients with diffuse large B-cell lymphoma

verfasst von: Keiichiro Fujii, Atsushi Inagaki, Ayako Masaki, Mariko Sugiura, Tomotaka Suzuki, Takashi Ishida, Shigeru Kusumoto, Shinsuke Iida, Hiroshi Inagaki

Erschienen in: Annals of Hematology | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Abstract

The international prognostic index (IPI) system has been widely used to predict prognosis in diffuse large B-cell lymphoma (DLBCL). However, this system categorizes DLBCL patients into four risk groups, and cannot optimize individualized prognosis. In addition, other clinicopathological factors, such as molecular aberrations, are not incorporated into the system. To partly overcome these weak points, we developed nomograms to predict individual patient survival. We also incorporated MYD88^L265P and CD79B^Y196 mutations into the nomograms since these mutations are associated with a worse prognosis and their signaling pathways have been highlighted as a therapeutic target. We analyzed 302 DLBCL cases for which multivariate analysis by Cox proportional hazard regression was performed. Nomograms for progression-free survival (PFS) and overall survival (OS) were constructed and assessed by a concordance index (C-index). The nomograms were also evaluated using an open external dataset (n = 187). The MYD88^L265P and/or CD79B^Y196 (MYD88/CD79B) mutation was detected in 62/302 patients. The nomograms incorporating IPI factors exhibited a C-index of 0.738 for PFS and a C-index of 0.765 for OS. The nomograms incorporating IPI factors and the MYD88/CD79B mutation showed a C-index of 0.745 for PFS and a C-index of 0.769 for OS. The nomograms we created were evaluated using an external dataset and were well validated. The present nomograms incorporating IPI factors and the MYD88/CD79B mutation have sufficient discrimination ability, and may effectively predict prognosis in DLBCL patients. The prognostic models we have presented here may help clinicians personalize prognostic assessments and clinical decisions.

Nur mit Berechtigung zugänglich

Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107(1):265–276. https://doi.org/10.1182/blood-2005-06-2508CrossRefPubMedPubMedCentral

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390. https://doi.org/10.1182/blood-2016-01-643569CrossRefPubMedPubMedCentral

Sehn LH, Salles G (2021) Diffuse Large B-Cell Lymphoma. N Engl J Med 384(9):842–858. https://doi.org/10.1056/NEJMra2027612CrossRefPubMedPubMedCentral

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503–511. https://doi.org/10.1038/35000501CrossRefPubMed

Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM, Lymphoma LM, Profiling P (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359(22):2313–2323. https://doi.org/10.1056/NEJMoa0802885CrossRefPubMedPubMedCentral

Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, Boyle M, Meissner B, Telenius A, Savage KJ, Sehn LH, Slack GW, Steidl C, Staudt LM, Connors JM, Rimsza LM, Gascoyne RD (2015) Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. J Clin Oncol 33(26):2848–2856. https://doi.org/10.1200/JCO.2014.60.2383CrossRefPubMedPubMedCentral

Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, Patti C, Belada D, Samoilova O, Suh C, Leppa S, Rai S, Turgut M, Jurczak W, Cheung MC, Gurion R, Yeh SP, Lopez-Hernandez A, Duhrsen U, Thieblemont C, Chiattone CS, Balasubramanian S, Carey J, Liu G, Shreeve SM, Sun S, Zhuang SH, Vermeulen J, Staudt LM, Wilsoninvestigators P W (2019) Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol 37(15):1285–1295. https://doi.org/10.1200/JCO.18.02403CrossRefPubMedPubMedCentral

Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schoder H, Zelenetz AD, Leonard JP (2019) Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol 37(21):1790–1799. https://doi.org/10.1200/JCO.18.01994CrossRefPubMedPubMedCentral

Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, Caddy J, Stanton L, Kazmi-Stokes S, McMillan A, Fields P, Pocock C, Collins GP, Stephens R, Cucco F, Clipson A, Sha C, Tooze R, Care MA, Griffiths G, Du MQ, Westhead DR, Burton C, Johnson PWM (2019) Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol 20(5):649–662. https://doi.org/10.1016/S1470-2045(18)30935-5CrossRefPubMedPubMedCentral

10.

Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, Ozcan M, Hong X, Zhu J, Jin J, Belada D, Bergua JM, Piazza F, Mocikova H, Molinari AL, Yoon DH, Cavallo F, Tani M, Yamamoto K, Izutsu K, Kato K, Czuczman M, Hersey S, Kilcoyne A, Russo J, Hudak K, Zhang J, Wade S, Witzig TE, Vitolo U (2021) ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. J Clin Oncol 39(12):1317–1328. https://doi.org/10.1200/JCO.20.01366CrossRefPubMedPubMedCentral

11.

Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Calaminici M, Sander B, Thorns C, Campo E, Molina T, Lee A, Pfreundschuh M, Horning S, Lister A, Sehn LH, Raemaekers J, Hagenbeek A, Gascoyne RD, Weller E (2011) Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 117(26):7070–7078. https://doi.org/10.1182/blood-2011-04-345256CrossRefPubMed

12.

Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Moller P, Cogliatti S, Lenz G, Trumper L, Loffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G, German High-Grade Lymphoma Study G (2017) Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. J Clin Oncol 35 (22):2515-2526https://doi.org/10.1200/JCO.2016.70.3660

13.

Phang KC, Akhter A, Tizen NMS, Rahman FA, Zahratul Azma R, Elyamany G, Shabani-Rad MT, Masir N, Mansoor A (2018) Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia. J Clin Pathol 71(3):215–220. https://doi.org/10.1136/jclinpath-2017-204548CrossRefPubMed

14.

Abdulla M, Hollander P, Pandzic T, Mansouri L, Ednersson SB, Andersson PO, Hultdin M, Fors M, Erlanson M, Degerman S, Petersen HM, Asmar F, Gronbaek K, Enblad G, Cavelier L, Rosenquist R, Amini RM (2020) Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma. Am J Hematol 95(1):57–67. https://doi.org/10.1002/ajh.25666CrossRefPubMed

15.

Cho I, Yoon N, Hyeon J, Sim J, Yoo HY, Kim SJ, Kim WS, Ko YH (2020) Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified. Appl Immunohistochem Mol Morphol 28(10):731–740. https://doi.org/10.1097/PAI.0000000000000843CrossRefPubMed

16.

Crotty R, Hu K, Stevenson K, Pontius MY, Sohani AR, Ryan RJH, Rueckert E, Brauer HA, Hudson B, Berlin AM, Rodenbaugh M, Licon A, Haimes J, Iafrate AJ, Nardi V, Louissaint A (2021) Simultaneous Identification of Cell of Origin, Translocations, and Hotspot Mutations in Diffuse Large B-Cell Lymphoma Using a Single RNA-Sequencing Assay. Am J Clin Pathol 155(5):748–754. https://doi.org/10.1093/ajcp/aqaa185CrossRefPubMed

17.

International Non-Hodgkin’s Lymphoma Prognostic Factors P (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–994. https://doi.org/10.1056/NEJM199309303291402CrossRef

18.

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857–1861. https://doi.org/10.1182/blood-2006-08-038257CrossRefPubMed

19.

Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6):837–842. https://doi.org/10.1182/blood-2013-09-524108CrossRefPubMedPubMedCentral

20.

Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, Haioun C, Tilly H, Ghesquieres H, Ziepert M, Flament J, Flowers C, Shi Q, Schmitz N (2020) International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood 135(23):2041–2048. https://doi.org/10.1182/blood.2019002729CrossRefPubMed

21.

Song JL, Wei XL, Zhang YK, Hao XX, Huang WM, Wei Q, Wei YQ, Feng R (2018) The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma. Zhonghua Xue Ye Xue Za Zhi 39(9):739–744. https://doi.org/10.3760/cma.j.issn.0253-2727.2018.09.007CrossRefPubMed

22.

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM (2018) Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378(15):1396–1407. https://doi.org/10.1056/NEJMoa1801445CrossRefPubMedPubMedCentral

23.

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trumper L, Getz G, Shipp MA (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24(5):679–690. https://doi.org/10.1038/s41591-018-0016-8CrossRefPubMedPubMedCentral

24.

Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470(7332):115–119. https://doi.org/10.1038/nature09671CrossRefPubMed

25.

Han Y, Yang J, Liu P, He X, Zhang C, Zhou S, Zhou L, Qin Y, Song Y, Sun Y, Shi Y (2019) Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. Oncologist 24(11):e1251–e1261. https://doi.org/10.1634/theoncologist.2018-0361CrossRefPubMedPubMedCentral

26.

Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJ, Oud ME, Scheepstra C, Kluin PM, Kersten MJ, Spaargaren M, Pals ST (2013) High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J 3(9):e139. https://doi.org/10.1038/bcj.2013.28CrossRefPubMedPubMedCentral

27.

Kim Y, Ju H, Kim DH, Yoo HY, Kim SJ, Kim WS, Ko YH (2014) CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Hum Pathol 45(3):556–564. https://doi.org/10.1016/j.humpath.2013.10.023CrossRefPubMed

28.

Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88–92. https://doi.org/10.1038/nature08638CrossRefPubMedPubMedCentral

29.

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282. https://doi.org/10.1182/blood-2003-05-1545CrossRefPubMed

30.

Akobeng AK (2007) Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr 96(5):644–647. https://doi.org/10.1111/j.1651-2227.2006.00178.xCrossRefPubMed

31.

Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, Schrag D, Saltz LB, Wong WD (2008) Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol 26(3):380–385. https://doi.org/10.1200/JCO.2007.14.1291CrossRefPubMed

32.

Montero PH, Yu C, Palmer FL, Patel PD, Ganly I, Shah JP, Shaha AR, Boyle JO, Kraus DH, Singh B, Wong RJ, Morris LG, Kattan MW, Patel SG (2014) Nomograms for preoperative prediction of prognosis in patients with oral cavity squamous cell carcinoma. Cancer 120(2):214–221. https://doi.org/10.1002/cncr.28407CrossRefPubMed

33.

Ali S, Palmer FL, Yu C, DiLorenzo M, Shah JP, Kattan MW, Patel SG, Ganly I (2014) Postoperative nomograms predictive of survival after surgical management of malignant tumors of the major salivary glands. Ann Surg Oncol 21(2):637–642. https://doi.org/10.1245/s10434-013-3321-yCrossRefPubMed

34.

Ali S, Palmer FL, Yu C, DiLorenzo M, Shah JP, Kattan MW, Patel SG, Ganly I (2013) A predictive nomogram for recurrence of carcinoma of the major salivary glands. JAMA Otolaryngol Head Neck Surg 139(7):698–705. https://doi.org/10.1001/jamaoto.2013.3347CrossRefPubMed

35.

Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, Kattan MW (2005) Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23(28):7005–7012. https://doi.org/10.1200/JCO.2005.01.867CrossRefPubMed

36.

Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, Van Zee KJ (2010) Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol 28(23):3762–3769. https://doi.org/10.1200/JCO.2009.26.8847CrossRefPubMed

37.

Brennan MF, Kattan MW, Klimstra D, Conlon K (2004) Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 240(2):293–298. https://doi.org/10.1097/01.sla.0000133125.85489.07CrossRefPubMedPubMedCentral

38.

Song JY, Perry AM, Herrera AF, Chen L, Skrabek P, Nasr M, Ottesen R, Nikowitz J, Bedell V, Murata-Collins J, Chen YY, Li Y, Gomez Luna C, McCarthy C, Pillai R, Wang J, Wu X, Zain J, Nademanee AP, Niland J, Gong Q, Chan WC, Weisenburger DD (2018) New Genomic Model Integrating Clinical Factors and Gene Mutations to Predict Overall Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Blood 132(Supplement 1):346–346. https://doi.org/10.1182/blood-2018-99-117636CrossRef

39.

Yu X, Li W, Deng Q, Li L, Hsi ED, Young KH, Zhang M, Li Y (2018) MYD88 L265P Mutation in Lymphoid Malignancies. Cancer Res 78(10):2457–2462. https://doi.org/10.1158/0008-5472.CAN-18-0215CrossRefPubMed

40.

de Groen RAL, Schrader AMR, Kersten MJ, Pals ST, Vermaat JSP (2019) MYD88 in the driver’s seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications. Haematologica 104(12):2337–2348. https://doi.org/10.3324/haematol.2019.227272CrossRefPubMedPubMedCentral

Titel: Nomogram for predicting survival of patients with diffuse large B-cell lymphoma
verfasst von: Keiichiro Fujii
Atsushi Inagaki
Ayako Masaki
Mariko Sugiura
Tomotaka Suzuki
Takashi Ishida
Shigeru Kusumoto
Shinsuke Iida
Hiroshi Inagaki
Publikationsdatum: 27.02.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 6/2024
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-024-05669-0

Thiotepa-busulfan-fludarabine-based conditioning as a promising approach prior to allogeneic hematopoietic stem cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm

Case Report

Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia

Original Article

Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel

Original Article

Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab

Open Access
Original Article

Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent β-thalassemia intermedia

Original Article

A nomogram model for predicting the efficacy of cyclosporine in patients with pure red cell aplasia

Original Article

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Vorsicht mit Glukokortikoiden bei Glomerulopathie

16.01.2025
Primäre Glomerulonephritiden
Nachrichten

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

16.01.2025
Zöliakie
Nachrichten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

15.01.2025
Urothelkarzinom
Nachrichten

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Einer von sieben Frauen macht die Menopause sehr zu schaffen

15.01.2025
Menopause
Nachrichten

Von mäßigen bis schweren vasomotorischen Beschwerden sind 14,7% der Frauen in der Postmenopause betroffen. Das haben kanadische Forscherinnen in einer Subgruppenanalyse der WARM-Studie herausgefunden.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Nomogram for predicting survival of patients with diffuse large B-cell lymphoma

Abstract

Weitere Artikel der Ausgabe 6/2024

Thiotepa-busulfan-fludarabine-based conditioning as a promising approach prior to allogeneic hematopoietic stem cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm

Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia

Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel

Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab

Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent β-thalassemia intermedia

A nomogram model for predicting the efficacy of cyclosporine in patients with pure red cell aplasia

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Neu im Fachgebiet Innere Medizin

Vorsicht mit Glukokortikoiden bei Glomerulopathie

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Einer von sieben Frauen macht die Menopause sehr zu schaffen

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten